With stocks up and down and all over the place during the past two months, investors are looking for a port in the storm. However, that doesn’t mean you have to give up on growth and power-packed portfolio performance. One space that has started to catch our eye of late is the medical suppliers.
There are three we want to focus on today as potentially interesting opportunities right now: Medtronic PLC (NYSE:MDT), Innovest Global Inc (OTCMKTS:IVST), and Becton Dickinson and Co (NYSE:BDX)
Medtronic PLC (NYSE:MDT) trumpets itself as a company that develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide.
It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities.
The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions.
The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain.
The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Medtronic PLC (NYSE:MDT) generated sales of $7.5B, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 1.3% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($10.1B against $8.5B).
Innovest Global Inc (OTCMKTS:IVST) casts itself as a diversified holding company, focuses on identifying and acquisition of qualified mineral prospects.
This is the more speculative name in the space. IVST is actually a conglomerate with operations outside of medical supply. But the company recently that its subsidiary just closed a four-year contract extension providing safety supplies to the University Hospital and Case Medical Center administration buildings in Cleveland, Ohio, helping to ramp anticipated performance.
This is a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers.
The company’s primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, it has a Commercial & Industrial Division, and a Biotechnology & Health Services Division.
The company recently took a strong stake in StemVax Therapeutics, a Translational Biotechnology Company that develops novel therapies for brain tumor patients. The company focuses its efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer.
The company also focuses its research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. It seeks to “make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics. Dr. Dwain Morris-Irvin, President of Innovest’s Biotech division is the StemVax founder and Chief Science Officer.”
Cedars-Sinai Medical Center is a non-profit hospital and academic health science center located in Los Angeles, California. They employ over 2,000 physicians and are considered one of the top hospitals and research organizations in the world. Dr. Irvin previously was one of their key contributors in the areas of research that he founded StemVax to pursue.
Innovest Global Inc (OTCMKTS:IVST) generated sales of $1.1M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth on the top line. In addition, the company has $390K in cash sitting on the balance sheet.
Becton Dickinson and Co (NYSE:BDX) trumpets itself as a company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($1.3B against $7.2B, respectively).
It operates in two segments, BD Medical and BD Life Sciences.
The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women’s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing.
BDX has been through some pressure over the past week. But recent news has helped to repair that damage and reset the action in terms of the past week’s performance.
Becton Dickinson and Co (NYSE:BDX) pulled in sales of $4.4B in its last reported quarterly financials, representing top line growth of 39%.